31 results about "Stem cell product" patented technology

Stem cells products having the potential to support cells of a soft tissue lineage, and methods of preparation and use of those stem cell products are disclosed. The invention also relates to methods for the use of such stem cells products in the regeneration and repair of soft tissue, and in cell-based therapies for of soft tissue conditions.

The invention discloses an umbilical cord mesenchymal stem cell preparation and a preparation method and application thereof. Through exploration and verification by a large quantity of experiments, the 3rd-10th-generation umbilical cord mesenchymal stem cells are selected as raw materials, and by a method of dispersing tissue by a mechanical method and then performing treatment with mixed enzymes containing collagenase I, collagenase II and trypsin for a short time for many times, the vitality of the separated umbilical cord mesenchymal stem cells is guaranteed. A culture medium special for the umbilical cord mesenchymal stem cell preparation, containing DMEM / F12 (without phenol red), 10% FBS, 20 kinds of amino acids and 8 kinds of vitamins, is adopted, mixed liquor of repeated cell culture supernatant and cell lysate supernatant is collected, more umbilical cord mesenchymal stem cell active protein and active factors are obtained, the preparation cost is reduced, and industrial requirements for a stem cell product preparation are met. The prepared umbilical cord mesenchymal stem cell preparation can promote proliferation of epidermic cells and skin fibroblast, is safe and is free from toxic and side effects, an allergy does not exist, and when the umbilical cord mesenchymal stem cell preparation is applied to feature-beautifying skin-care products, the effects are notable.

The described invention provides pharmaceutical compositions for treating an infarct area injury and methods of treating or repairing the infarct area injury in a revascularized subject in the aftermath of an acute myocardial infarction resulting from a natural disease process by administering to the subject parenterally through a catheter a sterile pharmaceutical composition containing a therapeutically effective amount of a nonexpanded sterile isolated chemotactic hematopoietic stem cell product as a first therapeutic agent and optionally a therapeutically effective amount of at least one compatible second therapeutic agent. The infarct area-improving amount of the sterile isolated chemotactic hematopoietic stem cell product comprises an enriched population of isolated autologous CD34+ cells containing a subpopulation of potent cells expressing CXCR-4 and having CXCR-4-mediated chemotactic activity such that the enriched population of isolated autologous CD34+ hematopoietic stem cells provides at least 0.5×106 potent CD34+ cells expressing CXCR-4 and having CXCR-4 mediated chemotactic activity.

The invention discloses an extraction and perfusion culture system for MSCs (Mesenchymal Stem Cells), belongs to a field of medical instruments, and more specifically, provides a set of continuous and completed system design for obtaining high-purity stem cell products from a placenta organ. The device provided by the invention comprises an extraction device and a perfusion culture system, and the extraction device and the perfusion culture system are connected hermetically and aseptically, wherein the extraction device comprises a placenta cutting device, a reaction tank, a filter device, a filtrate collection device and a density gradient centrifugation device; and the perfusion culture system comprises a culture solution storer, a monitoring reactor, a cell culture bottle, a liquid waste bottle, a bottle for obtaining liquid, a biochemical criterion detection head group, an online monitoring system, a speed control fluid propeller and a pipeline device capable of controlling speed. The extraction and perfusion culture system for the MSCs (Mesenchymal Stem Cells) has benefits that the cutting efficiency is high; the operation is convenient and effective; the production efficiency can be greatly improved; the preparation technology is simple; and the quality control is simple and convenient, so as to efficiently obtain uniform and good stem cell products within a short time.

The research group selects the optimum method for preparing a product of the invention, namely, enabling 100nM miR-21inhibitor transfected by lipo 2000 RNAimax to enter the stem cell. The stem cell product prepared by the method is enhanced in the capacity of secreting transforming growth factor TPF-beta 1, thus the capacity of inducing the T cell to differentiate towards regulatory T cells after co-culture of the cell and the T cell is enhanced, namely, the immunoregulation capacity of the stem cell is enhanced. In an in-vivo experiment, a medicine is adopted for inducing a mouse for establishing an acute enteritis model, the stem cell and a control cell which are transfected by miR-21 inhibitor are transfused into the body of the mouse through caudal vein by using the dosage of 1X10<6>, the result shows that the clinical symptoms and the immune indices of the mouse with stem cell group transfected by miR-21 inhibitor transfused are superior to those of the control cell group with transfusion, namely, the stem cell transfected by miR-21 inhibitor can be used for more effectively treating mouse enteritis. All in all, the stem cell with strong and stable effect is prepared, and experimental basis is provided for improving the application efficiency of the stem cell in clinic.

The present invention relates to pharmaceutical compositions comprising a chemotactic hematopoietic stem cell product comprising an enriched population of CD34+ cells containing a subpopulation of cells having chemotactic activity, methods of preparing these compositions and use of these compositions to treat or repair vascular injury, including infarcted myocardium.

The invention provides a stem cell and a preparation for treating retinosis. Through optimum culture and induced differentiation on mesenchymal stem cells, the efficiency for differentiating the cell into the retina nerve precursor cell is improved; the similar effect to that of the retina precursor cell is achieved in the aspect of the transplantation effect, so that the retina function in the transplantation region is effectively improved; an ideal cell source is provided for the treatment of retinosis diseases through stem cell transplantation; high superiority is realized. A preparation method of the stem cell preparation provided by the invention has the advantages that the preparation process of the stem cell product obtained through separation, culture, posterity pass-down and induction is simple and reliable; the repeatability is good. A use method of the stem cell preparation for treating retinosis provided by the invention belongs to a cell replacing method with the advantages that the operation is simple, the popularization is convenient, and the injury is small. Wide application prospects are realized. The method belongs to the best path for treating the retinosis type degenerative diseases and rescuing the vision.

The invention relates to a porcine mesenchymal stem cell culture solution and a preparation method thereof. The culture solution is prepared from the following components: a basal culture medium freeof animal-derived components, 2-20% of fetal calf serum and 5-10ng / mL of PDGF-BB factors. Compared with the conventional common mesenchymal stem cell culture solution, the porcine umbilical cord placenta mesenchymal stem cells cultured by the porcine mesenchymal stem cell culture solution have more typical cellular morphology, have higher cell passage capability, and are low in possibility of senescence; when the cells cultured by the porcine umbilical cord placenta mesenchymal stem cell culture solution is applied to production, porcine umbilical cord placenta mesenchymal stem cell products with higher quantity and more stable biological characteristics can be obtained.

The present invention discloses adipose-derived stem cells (ADSCs), adipose-derived stem cell-enriched fractions (ADSC-EF), their compositions and kits containing the ADSC's and their enriched fractions, and enzyme blends useful for their isolation, as well as methods of their isolation and use.

Provided are a sub-totipotent stem cell product and apparent hereditary modifying label thereof, a method for inducing the generation of the sub-totipotent stem cell product and identification for the apparent hereditary modifying label of the differentiated potential of stem cells. Also provided is a use of a histone modifying state of a sub-totipotent gene and / or differentiated related gene to predict the apparent hereditary modifying label of the differentiated potential of stem cells.

The invention discloses a preparation method of a bovine umbilical cord active ingredient extracting solution and an application of the extracting solution in human skin repair. According to the method, a supernatant containing bovine umbilical cord active ingredients is prepared with a method including cleaning, crushing, homogenizing and crushing and taking and filtering of the supernatant, andthe supernatant is adjusted to a stock solution with proper concentration. Glutathione is added to the stock solution in a certain proportion to increase the antioxidant function of skin, dipotassiumglycyrrhizinate is added to reduce the allergic reaction of skin, so that a human skin repair product is prepared and applied to repair of human skin. Compared with other cosmetic products, the extracting solution has the advantages that the problem of stem cell stemness loss generally exists in ordinary stem cell products is solved, all components of wharton's jelly in bovine umbilical cord are reserved, meanwhile, antioxidant and antiallergic components are added and have the synergistic effect with the bovine umbilical cord active ingredients, nutrition and repair of skin are better facilitated, and the extracting solution is low in cost and simple to prepare and has remarkable industrial application prospects.

A method of treating heart failure and improving cardiac function by administering stem cell products to a heart in need of treatment, whereby the stem cell products improve cardiac muscle function thereby treating heart failure and improving cardiac function. A method of enriching or regenerating damaged myocardium by administering stem cell products to damaged myocardium. Stem cell products for use in treating heart failure are also provided. A composition for enriching and regenerating damaged myocardium, the composition having stem cell products in a pharmaceutically acceptable carrier.

The invention discloses a hydro lifting instrument injection umbilical cord mesenchymal stem cell preparation and application thereof. The umbilical cord mesenchymal stem cell preparation is a stem cell suspension composed of umbilical cord mesenchymal stem cells and normal saline, wherein the total volume of the umbilical cord mesenchymal stem cells and the normal saline is 5 ml, and the total number of umbilical cord mesenchymal stem cells in the dry cell suspension is 1*10<6>-10<7>. A 9-needle type hydro lifting injection instruction is adopted, on the basis of the vacuum negative pressuretechnology, average coverage is performed on each unit area (1 cm<2>) through the same dosage, it is a new breakthrough that traditional point filling is replaced with face filling, umbilical cord mesenchymal stem cells are injected into a skin corium layer through the hydro lifting injection instrument, fixed-point, quantified and fixed-layer injection is performed, and the preparation has the effects of being free of traces and pain, uniform in injection, and convenient and rapid to use, performing treatment only for 10 min, and achieving the skin beautifying effects of smoothing skin, removing wrinkels, resisting skin aging and the like.

The invention discloses a rose glacier spring rejuvenating facial mask formula which comprises spring, rose hydrosol and various moisturizing and repairing ingredients. The various moisturizing and repairing ingredients specifically include: a main active ingredients and common ingredients; the main active ingredient is MetaTrixAPL-3 (first-generation stem cell products: MALUS DOMESTICA fruit cellculture extract, FRAGARIA VESCA fruit extract, GLYCINE SOJA seed extract, a hydrolyzed collagen, water, butanediol and 1,2-hexanediol; and effects: moisturization, wrinkle resistance and repairing).Specific effects of the ingredients in the rose glacier spring rejuvenating facial mask formula are that: the MALUS DOMESTICA fruit cell culture extract, the FRAGARIA VESCA fruit extract, the GLYCINESOJA seed extract, the hydrolyzed collagen, the water, the butanediol and the 1,2-hexanediol have effects of moisturizing, resisting to wrinkles and repairing; small molecule sodium hyaluronate has effects of moisturizing and resisting to wrinkles; sodium polyglutamate has effects of moisturizing and improving skin elasticity; and schizophyllin has effects of resisting to allergy, promoting woundhealing, resisting to ageing and moisturizing.

The invention relates to the technical field of stem cell culture, in particular to a serum-free medium (SFM) and application thereof in mesenchymal stem cell (MSC) subculture. An additive provided bythe invention is suitable for preparing the SFM for multiple passage of MSCs and effectively maintaining stemness, the defect of insufficient passage and amplification capacity of the MSCs can be overcome effectively, and a stable base material for realizing large-scale, standardized and industrialized production of stem cell products in the future is provided. Experiments show that the additivenot only can promote the amplification and passage of the MSCs, but also can well maintain the expression of surface markers of the MSCs, so that the cell stemness is effectively maintained.

The invention relates to highly proliferative stem cell obtained from menstrual fluid. The menstrual stern cells (MenSCs) may be cultured in vitro and exhibit mesenchymal stem cell (MSC)-like properties and some culture and expansion advantages. This population of MenSCs, compared to the broadly studied bone marrow derived stem cells (BM-MSCs) out-performs bone marrow derived mesenchymal stem cells in proliferation rate and support of hematopoietic stem cell (HSC) expansion in vitro. MenSCs demonstrate to maintain their stem cell properties over 2 years, being genetically stable, without expressing surface differentiation markers, and they also show the ability to differentiate into adipocytes, chondrocytes and osteoblast cells. MenSCs can be easily and periodically obtained, isolated and cultured.

The invention discloses a cryopreservation solution and a cryopreservation method for long-term preservation of stem cells and stem cell products. The cryopreservation liquid is prepared from the following raw materials in parts by weight: 10 to 15 parts of low-molecular dextran, 2 to 8 parts of hydroxyethyl starch, 10 to 15 parts of chitosan, 3 to 6 parts of glycerol, 3 to 6 parts of dimethyl sulfoxide, 20 to 30 parts of glucose injection, 10 to 15 parts of compound amino acid injection and 20 to 30 parts of compound electrolyte injection. Under the combined action of the low-molecular dextran, the hydroxyethyl starch, the glucose injection, the compound amino acid injection and the compound electrolyte injection, the system balance of ion osmotic pressure and colloid osmotic pressure is maintained, an environmental condition beneficial to the survival of the stem cells is formed, and the long-term preservation of the stem cells is facilitated.

The present invention relates to methods and compositions for treating hematological malignancies using amplified hematopoietic stem cell products in combination with chemotherapy regimens.

The invention discloses a stem cell-based medicinal product storing and conveying device. A cold insulation structure is arranged on the periphery in a vacuum bottle, and is provided with a refrigeration bag, and the refrigeration bag is a flat bag sealed peripherally. The refrigeration bag is subjected to hot press fitting at equal intervals left and right to form four linear bonding strips, andthe four linear bonding strips divide the refrigeration bag into five separation areas. The refrigeration bag is filled with a refrigerant, the five separation areas are arranged on the periphery in the vacuum bottle in a surrounding manner, and a stem cell-based product, such as a stem cell-based medicinal product or a container, is arranged in the middle in the vacuum bottle, and a buffering padis arranged between the stem cell-based product and the cold insulation structure. According to the stem cell-based medicinal product storing and conveying device, the cold insulation structure is arranged in the vacuum bottle, and therefore a low-temperature environment can be kept in the vacuum bottle, and the effects that stem cells can be stored and conveying is easy due to the size are achieved.

The invention provides a melanoma-resistant stem cell patch. The stem cell patch has a mesenchymal stem cell molecular mark and a biological characteristic, low immunogenicity, does not cause immunological rejection, and by adding effective factors aiming at melanoma, the melanoma can be effectively treated and restored. The invention further provides a preparation method of the stem cell patch, and the preparation method comprises the following steps: preparing a mesenchymal stem cell from bone marrows, preparing and pretreating a biomembrane, constructing a mesenchymal stem cell biomembrane, inducing the mesenchymal stem cell biomembrane, and forming the melanoma-resistant stem cell patch. The method adopts stem cell products with wide sources, the preparation process is simple and reliable and the reproducibility is good.

The invention provides a stem cell and a preparation for treating retinosis. Through optimum culture and induced differentiation on mesenchymal stem cells, the efficiency for differentiating the cell into the retina nerve precursor cell is improved; the similar effect to that of the retina precursor cell is achieved in the aspect of the transplantation effect, so that the retina function in the transplantation region is effectively improved; an ideal cell source is provided for the treatment of retinosis diseases through stem cell transplantation; high superiority is realized. A preparation method of the stem cell preparation provided by the invention has the advantages that the preparation process of the stem cell product obtained through separation, culture, posterity pass-down and induction is simple and reliable; the repeatability is good. A use method of the stem cell preparation for treating retinosis provided by the invention belongs to a cell replacing method with the advantages that the operation is simple, the popularization is convenient, and the injury is small. Wide application prospects are realized. The method belongs to the best path for treating the retinosis type degenerative diseases and rescuing the vision.

The invention discloses a culture additive for in-vitro induction of stem cells to insulin-secretion cells differentiation maturation and a purpose of the culture additive in stem cell induction differentiation. The additive can promote in-vitro differentiation of stem cells with various sources to insulin-secretion cells, which comprises pancreas tissue-derived adult stem cells, induced pluripotent stem cells (iPS cells), or other tissue-derived stem cells. The culture additive comprises the main components of glucagon-like peptide1 or its analogue, niacinamide, and 1,25-(OH)2D3. The cultureadditive can be matched with any basic medium for usage, and the efficiency for induction of stem cell differentiation to the insulin-secretion cells and the cell maturity after differentiation are good. The culture additive can be used for induction differentiation of the stem cell to the insulin-secretion cells, so that the stem cell products capable of substituting pancreas islet function can be prepared.

The invention provides a primer pair and a kit for rapidly detecting mycoplasma and application of the primer pair and the kit and belongs to the technical field of mycoplasma detection. The primer pair comprises an upstream primer and a downstream primer; a nucleotide sequence of the upstream primer is shown as SEQ ID NO.1 or SEQ ID NO.2; and a nucleotide sequence of the downstream primer is shown as SEQ ID NO.3 or SEQ ID NO.4. The primer pair provided by the invention can specifically detect the mycoplasma, has no specificity to genes of human-origin cells and mouse-origin cells, can realizequantitative detection on the mycoplasma a limit of detection being 3.1*10-2.8-107 copies when being used for QPCR. The primer can realize rapid, extensive, high-sensitivity and quantifiable detection of the mycoplasma, is applied to the field of mycoplasma detection and is more suitable for mycoplasma detection in clinical research and application of cell and stem cell products.

The invention discloses a preparation method of a bovine umbilical cord active ingredient extracting solution and an application of the extracting solution in human skin repair. According to the method, a supernatant containing bovine umbilical cord active ingredients is prepared with a method including cleaning, crushing, homogenizing and crushing and taking and filtering of the supernatant, andthe supernatant is adjusted to a stock solution with proper concentration. Glutathione is added to the stock solution in a certain proportion to increase the antioxidant function of skin, dipotassiumglycyrrhizinate is added to reduce the allergic reaction of skin, so that a human skin repair product is prepared and applied to repair of human skin. Compared with other cosmetic products, the extracting solution has the advantages that the problem of stem cell stemness loss generally exists in ordinary stem cell products is solved, all components of wharton's jelly in bovine umbilical cord are reserved, meanwhile, antioxidant and antiallergic components are added and have the synergistic effect with the bovine umbilical cord active ingredients, nutrition and repair of skin are better facilitated, and the extracting solution is low in cost and simple to prepare and has remarkable industrial application prospects.

The present method relates to methods of expanding or increasing stem cell production obtained from donor samples. The methods preferably including the steps of harvesting cells from minimally manipulated tissue using multiply harvesting cycles to increase the number of obtained stem cells.

A method for enhancing bone marrow cells, peripheral blood, and umbilical cord blood engraftment is disclosed wherein at least one of a granulocyte colony stimulating factor and a granulocyte macrophage colony stimulating factor, and optionally romiplostim, and optionally an erythropoiesis-stimulating agent, are added thereto for enhancing the engraftment of CD44 cells within the bone marrow cells, peripheral blood, and umbilical cord blood. Also provided is a method for enhancing a stem cell infusion by activating an up-regulation of a AF1q / CD44 signaling pathway. A stem cell product is disclosed having treated stem cells conditioned for activating an up-regulation of a AF1q / CD44 signaling pathway.

The invention discloses a cryopreservation solution and a cryopreservation method for stem cells and products thereof. The cryopreservation liquid comprises the following raw materials in parts by weight: 10-15 parts of trehalose, 10-20 parts of EDTA (Ethylene Diamine Tetraacetic Acid), 5-8 parts of methylcellulose, 3-5 parts of glycerol, 3-5 parts of dimethyl sulfoxide and 100-120 parts of a culture medium. The cryopreservation liquid is prepared from trehalose, EDTA, methyl cellulose, glycerin, dimethyl sulfoxide and a culture medium, trehalose can serve as a protection component of the cryopreservation liquid, and EDTA can provide a reduction environment for cryopreserved cells; the methylcellulose can improve the anti-apoptosis and anti-oxidation capacities of the frozen stock solution after recovery; glycerin and dimethyl sulfoxide are used in cooperation, so that permeable components of the cryopreservation liquid can rapidly penetrate through cell membranes to enter cells, the freezing point is reduced, the cryopreservation process is delayed, the ion concentration in the cells is improved, formation of ice crystals in the cells is reduced, and therefore the cell damage degree is reduced; the potential toxic effect on cells is reduced.

The invention provides a mesenchymal stem cell refrigeration protection liquid and a preservation method. The refrigeration protection liquid comprises the following components: trehalose, a low-molecular heparin calcium injection, a dextran 40 sodium chloride injection, human serum albumin and a compound electrolyte injection. The cold storage protection liquid does not contain toxicological components such as DMSO (dimethylsulfoxide) and the like, and the components are all injection-grade medicine auxiliary materials approved by the country and can be directly transfused back into veins. By adopting a pre-cooling type refrigeration preservation method, the cells and the protection liquid can quickly enter a low-temperature equilibrium state so as to reduce cell damage, the method can be used for long-time preservation of the mesenchymal stem cells under the refrigeration condition of 4 DEG C, is convenient to transport, and reduces the dependence of stem cell products on regions.

A construction method of a stem cell bank for preventing and treating novel coronavirus pneumonia comprises the following steps of: collecting residual amniotic fluid cells, newborn umbilical cord blood, umbilical cord and placenta tissues after prenatal diagnosis, carrying out stem cell induction, immortalized gene transfection, novel coronavirus targeted interference gene assembly, novel coronavirus susceptibility gene knockout or knock-in and novel coronavirus antibody generation gene assembly to prepare immortalized stem cells, DNA recombinant stem cells, RNA interference stem cells, gene silencing stem cells and various stem cell vector vaccines for preventing and treating novel coronavirus pneumonia, collecting the prepared stem cell products in -196 DEG C liquid nitrogen in a centralized mode according to donor names, ABO blood types or HLA types, and establishing a renewable special stem cell bank. When the novel coronavirus is epidemic, various types of stem cells or vaccines thereof can be extracted from the stem cell bank to be cultured and amplified, and individualized treatment is performed by the patient's own or homologous stem cells, so that side effects such as immunological rejection and the like of traditional stem cell or vaccine prevention and treatment are reduced, and the problem of lack of COVID-19 special-effect medicines and stem cells is solved.